ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company, has successfully converted its convertible promissory notes, eliminating over $4 million in long-term debt. This strategic move significantly strengthens ANEW's balance sheet and increases stockholder equity, positioning the company for future growth and investment opportunities. The debt conversion also eliminates $600,000 in annual interest payments.
The average conversion price was approximately $1.08 per share, reflecting investors' long-term commitment to the company. Jeffrey LeBlanc, ANEW's Chief Financial Officer, stated that this debt conversion demonstrates strong investor confidence in ANEW's growth potential and strategic direction. The newly achieved debt-free status provides ANEW with increased financial flexibility to invest more aggressively in its cutting-edge research and development of cell and gene-based treatments for aging and age-related diseases.
ANEW MEDICAL, INC. (NASDAQ: WENA), una delle principali aziende biotecnologiche statunitensi, ha convertito con successo le sue obbligazioni convertibili, eliminando oltre 4 milioni di dollari di debito a lungo termine. Questa mossa strategica rafforza significativamente il bilancio di ANEW e aumenta l'equità degli azionisti, posizionando l'azienda per future opportunità di crescita e investimento. La conversione del debito elimina anche 600.000 dollari di pagamenti annuali di interessi.
Il prezzo medio di conversione è stato di circa 1,08 dollari per azione, riflettendo l'impegno a lungo termine degli investitori verso l'azienda. Jeffrey LeBlanc, Chief Financial Officer di ANEW, ha dichiarato che questa conversione del debito dimostra una forte fiducia degli investitori nel potenziale di crescita e nella direzione strategica di ANEW. Lo stato di assenza di debiti recentemente raggiunto fornisce ad ANEW una maggiore flessibilità finanziaria per investire in modo più aggressivo nella sua ricerca e sviluppo all'avanguardia su trattamenti basati su cellule e geni per l'invecchiamento e le malattie legate all'età.
ANEW MEDICAL, INC. (NASDAQ: WENA), una destacada compañía de biotecnología de EE. UU., ha convertido con éxito sus notas promisorias convertibles, eliminando más de 4 millones de dólares en deuda a largo plazo. Este movimiento estratégico refuerza significativamente el balance de ANEW y aumenta el patrimonio de los accionistas, posicionando a la empresa para futuras oportunidades de crecimiento e inversión. La conversión de la deuda también elimina 600,000 dólares en pagos de intereses anuales.
El precio promedio de conversión fue de aproximadamente 1.08 dólares por acción, reflejando el compromiso a largo plazo de los inversionistas con la empresa. Jeffrey LeBlanc, Director Financiero de ANEW, afirmó que esta conversión de deuda demuestra una sólida confianza de los inversionistas en el potencial de crecimiento y la dirección estratégica de ANEW. El nuevo estado de libre de deuda proporciona a ANEW una mayor flexibilidad financiera para invertir de manera más agresiva en su investigación y desarrollo de tratamientos innovadores basados en células y genes para el envejecimiento y enfermedades relacionadas con la edad.
ANEW MEDICAL, INC. (NASDAQ: WENA), 미국의 선도적인 생명공학 회사는 전환사채를 성공적으로 전환하여 4백만 달러 이상의 장기 부채를 없앴습니다. 이 전략적 움직임은 ANEW의 재무 상태를 크게 강화하고 주주 자본을 증가시켜 회사의 미래 성장 및 투자 기회를 위한 기반을 마련합니다. 부채 전환은 또한 60만 달러의 연간 이자 지급을 없애는 효과도 있습니다.
평균 전환 가격은 약 1.08달러 per 주로, 투자자들의 회사에 대한 장기적인 신뢰를 반영하고 있습니다. ANEW의 최고 재무 책임자 제프리 레블랑은 이번 부채 전환이 ANEW의 성장 잠재력과 전략적 방향에 대한 강한 투자자 신뢰를 보여준다고 밝혔습니다. 새로 확보된 무부채 상태는 ANEW에게 세포 및 유전자 기반의 노화 및 노화 관련 질병 치료를 위한 최첨단 연구 및 개발에 더 공격적으로 투자할 수 있는 재정적 유연성을 제공합니다.
ANEW MEDICAL, INC. (NASDAQ: WENA), une entreprise de biotechnologie américaine de premier plan, a réussi à convertir ses billets à ordre convertibles, éliminant ainsi plus de 4 millions de dollars de dettes à long terme. Ce mouvement stratégique renforce considérablement le bilan d'ANEW et augmente l'équité des actionnaires, positionnant l'entreprise pour de futures opportunités de croissance et d'investissement. La conversion de la dette élimine également 600 000 dollars de paiements d'intérêts annuels.
Le prix moyen de conversion était d'environ 1,08 dollar par action, reflétant l'engagement à long terme des investisseurs envers l'entreprise. Jeffrey LeBlanc, directeur financier d'ANEW, a déclaré que cette conversion de la dette démontre la forte confiance des investisseurs dans le potentiel de croissance et l'orientation stratégique d'ANEW. Le nouvel état sans dette offre à ANEW une plus grande flexibilité financière pour investir plus agressivement dans sa recherche et du développement de traitements de pointe basés sur des cellules et des gènes pour le vieillissement et les maladies liées à l'âge.
ANEW MEDICAL, INC. (NASDAQ: WENA), ein führendes Biotechnologieunternehmen in den USA, hat erfolgreich seine wandelbaren Schuldverschreibungen umgewandelt und über 4 Millionen Dollar an langfristigen Schulden eliminiert. Dieser strategische Schritt stärkt die Bilanz von ANEW erheblich und erhöht das Eigenkapital der Aktionäre, wodurch das Unternehmen für zukünftiges Wachstum und Investitionsmöglichkeiten positioniert wird. Die Schuldenumwandlung beseitigt zudem 600.000 Dollar an jährlichen Zinszahlungen.
Der durchschnittliche Umwandlungspreis lag bei etwa 1,08 Dollar pro Aktie, was das langfristige Engagement der Investoren für das Unternehmen widerspiegelt. Jeffrey LeBlanc, Chief Financial Officer von ANEW, erklärte, dass diese Schuldenumwandlung das starke Vertrauen der Investoren in das Wachstumspotenzial und die strategische Ausrichtung von ANEW demonstriert. Der neu erreichte schuldenfreie Status gibt ANEW eine erhöhte finanzielle Flexibilität, um aggressiver in seine hochmodernen Forschungs- und Entwicklungsprojekte für zell- und genbasierte Therapien gegen das Altern und altersbedingte Krankheiten zu investieren.
- None.
- None.
Successful Conversion Eliminates Over
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over
The elimination of over
“This debt conversion reflects the strong confidence our investors have in ANEW’s growth potential and strategic direction,” said Jeffrey LeBlanc, ANEW’s Chief Financial Officer. “By emerging long-term debt-free, we gain significant financial flexibility, which allows us to invest more aggressively in our cutting-edge research and development.”
With a solid financial foundation, ANEW is well-positioned to advance its innovative research pipeline targeting the growing market of age-related diseases. The company remains committed to delivering transformative therapies that improve quality of life for aging populations worldwide.
About ANEW MEDICAL, INC.
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Investor Relations
Email: IR@anewmeds.com
Website: https://www.anewmeds.com/press-releases/
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
How much long-term debt did ANEW MEDICAL, INC. (WENA) eliminate through the conversion of promissory notes?
What was the average conversion price for ANEW MEDICAL's (WENA) promissory notes?
How much will ANEW MEDICAL (WENA) save annually in interest payments after the debt conversion?
What is the main focus of ANEW MEDICAL's (WENA) research and development?
How does the debt conversion affect ANEW MEDICAL's (WENA) financial flexibility?
